Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. On 9 December 2025, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 35 partnership shares in Haleon at a price of £3.57201 per ordinary share and received 35 matching shares at no cost. These ordinary shares have a nominal value of £0.01 each and are listed on the London Stock Exchange. The disclosure is made in line with UK Market Abuse Regulation requirements for transactions by persons discharging managerial responsibilities.
Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reported PDMR share transactions under its Share Reward Plan. On 11 November 2025, Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 33 ordinary shares at £3.718992 and received 33 matching shares at £Nil on the London Stock Exchange.
These notifications were made in accordance with the UK Market Abuse Regulation and reflect routine participation in the company’s employee share plan.
Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Banga has served as Senior Independent Director since Haleon’s 2022 listing and brings extensive global consumer leadership experience, including 33 years at Unilever and roles at UK Government Investments and GSK. The Board’s decision was unanimous. Remuneration details and a successor for Senior Independent Director will be announced before his appointment takes effect.
Haleon plc reported its total voting rights and capital. As at 31 October 2025, the Company had 8,952,353,648 ordinary shares issued, including 45,930,962 held as treasury shares. After excluding treasury shares, the number of ordinary shares with voting rights is 8,906,422,686.
This voting-rights figure is the denominator shareholders and other obliged parties should use when assessing notification thresholds under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.
The Company will host a short presentation and Q&A at 9:00am GMT (10:00am CET) on 30 October 2025, led by Chief Financial Officer Dawn Allen, with access via www.haleon.com/investors.
Dial-in details include UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228. An archived webcast will be available later the same day.
Haleon plc filed a Form 6-K reporting notifications of transactions by persons discharging managerial responsibilities on 10 October 2025. The disclosure shows an allotment of £3.4352 per share for 37 matching shares as the reported trade. The notice is a regulatory disclosure under the UK Market Abuse Regulation and provides routine transparency about insider dealings. The report lists the company's well-known consumer health brands and is signed by the Company Secretary on 10 October 2025.
Haleon plc filed a Form 6-K notifying investors that Tracy Clarke, a current Non-Executive Director of Haleon, will be appointed as a Non-Executive Director of Inchcape plc effective 31 December 2025. The disclosure was made to satisfy paragraph 6.4.9R(2) of the UK Listing Rules and is presented as a director declaration in the exhibit. The report is dated 02 October 2025 and signed by Amanda Mellor, Company Secretary. The filing reiterates Haleon’s consumer health focus and lists major product categories and brands for context.
Haleon plc has announced the purchase of 1,561,229 ordinary shares under the second tranche of its share buyback programme and intends to hold these shares as treasury stock. After settlement, the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, with 45,962,012 held as treasury shares, leaving 8,906,391,636 voting shares. The announcement confirms completion of the final tranche of the buyback programme launched 28 March 2025. Since the start of the year, including shares acquired from Pfizer, Haleon repurchased 175,806,525 shares: 131,372,271 were cancelled and 44,434,254 remain as treasury shares. A full trade breakdown is available via the provided link.
Haleon plc reports its total issued share capital and voting rights as of 30 September 2025. The company has 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held in treasury, leaving 8,907,952,865 ordinary shares with voting rights. Shareholders and others with notification obligations should use 8,907,952,865 as the denominator when assessing disclosure thresholds under the FCA's Transparency Rules. The filing provides a contact for notifiable interests (company.secretary@haleon.com) and a brief company description of Haleon’s consumer health business and major brands.